会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Use of esters of long-chain fatty acids for treatment of autoimmune diseases
    • 使用长链脂肪酸酯来治疗自身免疫性疾病
    • US08614248B2
    • 2013-12-24
    • US10474696
    • 2002-04-11
    • Pinchas BursteinAvraham Ben-Nun
    • Pinchas BursteinAvraham Ben-Nun
    • A01N43/04A01N43/00A61K31/70A61K31/33
    • A61K31/7024A61K31/23A61K31/231A61K31/232A61K2300/00
    • Agents selected from: (i) a C1-C24 alkyl ester of a saturated or cis-unsaturated C10-C24 fatty acid; (ii) a monoester or polyester of a polyol having at least four hydroxy groups with a saturated or cis-unsaturated C10-C24 fatty acid or an anhydro derivative thereof; (iii) a monoester or polyester of a mono-, di- or poly-saccharide with a saturated or cis-unsaturated C10-C24 fatty acid; (iv) an amide of a saturated or cis-unsaturated C10-C24 fatty acid with an aliphatic or aromatic amine or with an amino acid, peptide, protein or aminosaccharide; and (v) combinations of any of (i) to (iv), can be used for treatment of autoimmune diseases and other immune-associated inflammatory disorders. Preferred agents are ethyl oleate and mannide monooleate or a combination thereof.
    • 选自以下的试剂:(i)饱和或顺式不饱和C10-C24脂肪酸的C1-C24烷基酯; (ii)具有至少四个羟基的饱和或顺式不饱和C 10 -C 24脂肪酸或其脱水衍生物的多元醇的单酯或聚酯; (iii)具有饱和或顺式不饱和C10-C24脂肪酸的单糖,二糖或多糖的单酯或聚酯; (iv)饱和或顺式不饱和的C 10 -C 24脂肪酸与脂族或芳族胺或氨基酸,肽,蛋白质或氨基糖的酰胺; 和(v)(i)至(iv)中任一项的组合可用于治疗自身免疫性疾病和其他免疫相关性炎症性疾病。 优选的试剂是油酸乙酯和单油酸甘露酯或其组合。
    • 3. 发明授权
    • Synthetic peptides and DNA sequences for treatment of multiple sclerosis
    • 用于治疗多发性硬化症的合成肽和DNA序列
    • US08012487B2
    • 2011-09-06
    • US10492794
    • 2002-10-17
    • Avraham Ben-NunNicole Kerlero De Rosbo
    • Avraham Ben-NunNicole Kerlero De Rosbo
    • A61K39/00
    • C07K14/4713A61K38/00
    • Synthetic unaltered and altered peptides comprising sequences of at least one immunogenic epitope cluster (IEC) of at least one human autoantigen related to multiple sclerosis (MS) and at least one nonameric core sequence which fits into the MS-relevant HLA-DR/DQ molecule and is flanked by 2-5 amino acids at its N- and C-termini, are provided. The alteration is preferably by substituting 1 to 3 TCR contact residues by Ala. The autoantigen is preferably MOG, MBP, OSP, MOBP and PLP. Polypeptides comprising at least two such peptides of a sole autoantigen or at least one peptide of two different autoantigens, and synthetic genes encoding them, are also provided, as well as pharmaceutical compositions for treatment and diagnostic of MS.
    • 合成未改变和改变的肽,其包含至少一种与多发性硬化(MS)有关的至少一种人自身抗原的免疫原性表位簇(IEC)和至少一种适合于MS相关HLA-DR / DQ分子的非标准核心序列的序列 并在其N-和C-末端侧接2-5个氨基酸。 优选通过用Ala代替1〜3个TCR接触残基,自身抗原优选为MOG,MBP,OSP,MOBP和PLP。 还提供了包含至少两种这样的单独自身抗原肽或两种不同自身抗原的至少一种肽的多肽以及编码它们的合成基因,以及用于治疗和诊断MS的药物组合物。